Academy Medal Recipients

Eminent Fellows

Academy Medal Recipients

The Academy Medal is awarded to individuals in recognition of the contributions they have made to both national and international pharmaceutical science.

Medal Recipients

Dr John Clements
The first part his professional life was in academia, following a year�s experience of working in research and development, manufacture and quality control in a small pharmaceutical company. In academia he conducted a strong research programme centred on biopharmaceutics and clinical pharmacokinetics, and taught these subjects at the undergraduate and postgraduate levels. For ten years John ran the continuing education programme for pharmacists in the Lothian Region. On leaving academia he joined a contract research organisation where he was successively head of analytical services and head of clinical support services. John was responsible for the design and execution of study protocols to meet the needs for product registration. His work at the Royal Pharmaceutical Society has been in the science area, through support of the committee work of the Society and its science consultations, and through the provision of a portfolio of science events. John has also acted in an out-reach capacity through contacts with other professional and scientific organisations, both national and international. Latterly, he has provided these services to the Society on a part-time contracted basis. Qualifications: BPharm, University of London, 1962 MPS (subsequently MRPharmS) 1963 PhD, University of London 1968 Leisure activities: Cycling, sailing, non-fiction reading, golf, badminton, tennis

Prof Bill Dawson
Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years service and established Bionet Ltd as a health care consultancy working at the interface between academia and industry. At Lilly, Bill was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Latterly, he was Director of Technology Acquisition, Europe, for Lilly. He continues to be a member of the ABPI Academic Liaison Working Group. He is Director of the University of Manchester Medicines Network. He is a non-executive director of Proteome Sciences plc, Antitope Ltd, Pharmovation Ltd and a member of a number of corporate Scientific Advisory Boards. Previously, he was a Director of Biovation Ltd, purchased by Merck KGaA, Enzacta Ltd, merged to form Enact Pharma Ltd and now part of Protherics plc and the Babraham Institute where he served the maximum two terms. He was a Board Member of the Pharmaceutical Licensing Group from 1994-2005. PLG is the professional organisation representing the majority of licensing executives in the UK. He has been active in peer review for MRC, EPSRC and BBSRC and has participated in a number of DTI grant and review panels. He is a Visiting Professor in the School of Science and Mathematics at Sheffield Hallam University and is a Governor of the University of Brighton and of De Montfort University. He is a Fellow of the School and was previously a member of staff in the pharmacology department having completed his PhD at the School under Professor Geoffrey B West Professor Dawson qualified as a pharmacist and specialised in pharmacology. His research interests are in immunopharmacology and in the rational design, selection and progression of new medicines through optimal research and development programmes.

Dr Chris Doherty
Chris is a Pharmacist by education and followed this with a PhD in Pharmaceutical Technology, postdoctoral studies at the University of Toronto, Canada and later an MBA. He has worked for Glaxo R&D; in the UK and Canada, Roche R&D; in the UK, Astra R&D; UK and now AstraZeneca. His current role involves responsibility for pharmaceutical and analytical R&D; activities at the AstraZeneca sites in the UK and the USA. Chris has been Treasurer and Chairman for the APS and am currently a board member of the EUFEPS Executive Committee and remain a Board member of the APS. Current position(s): Vice-President, Pharmaceutical & Analytical R&D;,AstraZeneca

Dr Tommy Dolan
Tommy completed his undergraduate and postgraduate education in Pharmacy at the University of Strathclyde. Following that he undertook post doctoral study at the universities of Strathclyde and Glasgow assessing novel drug carrier systems as immunological adjuvants. He first joined Controlled Therapeutics in 1988 where he was involved in researching the use of hydrogels as novel drug delivery systems for a range of indications. In 1990 Tommy commenced his career at Pfizer Global Research and Development at Sandwich joining as a formulation scientist. Since joining Pfizer he has held a variety of positions in Pharmaceutical Research and Development in that time ultimately heading the department since 2002. Tommy has been involved in the development of a number of drug development programs and wide variety dosage form types in that time many of which are now marketed products. Tommy currently head the departments of Analytical and Pharmaceutical Research and Development at Sandwich and is a past Chair of the Academy of Pharmaceutical Sciences.

Dr Eddie French
Eddie French is an independent pharmaceutical consultant who specializes in therapeutic product design and development, for both large and small molecules, cellular therapies and drug delivery devices. He is currently attached, on a part time basis, to the University of Bath, Department of Pharmacy, where he is an honorary professor and director of biopharmaceutical development for the ReMedDes consortium. Eddie has over 20 years experience in the pharmaceutical industry, the last 17 of which were spent with Pfizer Sandwich, where he was a director within Pharmaceutical Sciences working on a wide range of preclinical, clinical and commercial dosage forms.Prior to his industrial career, he was a lecturer in pharmaceutics. Eddie is a previous chair of the Academy of Pharmaceutical Sciences and is currently on the board as the immediate past chair. In addition to his role at Bath, Eddie is also the honorary professor of formulation science at the University of Nottingham.

Mrs Christine Glover F.R.P.S.
Mrs Christine Glover BSc, FRPharmS, MIPharmM, LFHom Elected Fellow of Royal Pharmaceutical Society of Great Britain - December 1996 Awarded Gold Medal by Academy of Pharmaceutical Science - 2000 Pharmacist - Owner of Glovers Integrated Healthcare in Edinburgh (Previously independent proprietor of Glovers Pharmacy in Edinburgh. (1983 -1998) Current Positions Royal Pharmaceutical Society (Professional & Regulatory body for all 45,000 pharmacists in GB.) Chairman of Trustees for RPS Pension Fund (managing �40 million) Other Director College of Medicine Appointed to MHRA Committee for Safety of Devices May 2005 (reappointed 2009) Appointed as Lay Chairman of MHRA Expert Advisory Group 2007 Member of MHRA Topic Selection Panel for novel technology Member of 2 advisory panels for a global pharmaceutical company Member of Professional Advisory Board for Migraine Action Association Member of advisory board for Academy of Pharmaceutical Sciences Previous experience Royal Pharmaceutical Society of Great Britain Member of Council (1991-2005) President 1998-2001 (Re-elected unopposed for second term) Chairman of RPSGB Benevolent Fund Steering Group (managing �11 million) Chairman and/or member of numerous committees and working parties for RPSGB, including Practice Committee, Corporate Governance Steering Group and Shipman Working party. Member of the Scottish Executive of RPSGB (1988-2005) International Pharmaceutical Federation (FIP) Member of Community Pharmacy Section Executive 1998-2004 Institute of Chartered Accountants Scotland Lay member of Council 2002 � 2007 Member of Executive Group and of Nominating Committee Member of Corporate Governance Steering Group Member of Review Group on Disciplinary Procedures Other Served on Government working parties for CMO, Scottish Executive and BMA. Gave evidence to House of Commons select committee on Drug Abuse Global experience in lecturing, running courses, and public speaking. Achievements Instigated and oversaw complete overhaul of corporate governance for Council of RPSGB. As lay Chairman, chaired Expert Advisory Group, and oversaw successful report, on muta-genicity of metal debris from metal-on-metal hip replacements. Raised profile of pharmacy with Government, media and public during 2 years of presidency. Facilitated linking pharmaceutical science with pharmaceutical practice.

Prof Tony Moffat
Tony is Professor of Pharmaceutical Analysis at The School of Pharmacy, University of London where he heads the Centre for Pharmaceutical Analysis. The Centre provides a focus for research and education in pharmaceutical analysis within The School and is extending the world-class knowledge base in that field. In particular, Near-Infrared Spectroscopy is being used: to further the technique, increase its use in the pharmaceutical industry and get it accepted by the regulatory authorities. He was previously Chief Scientist at the Royal Pharmaceutical Society of Great Britain where he gave advice on scientific matters to the Society�s Council and other departments within the Society. Part of his duties was to write policy papers concerning the scientific aspects of pharmaceutical health care and how it may be delivered to the community at large. He has extensive knowledge at first-hand of pharmacy in the community, academic and hospital settings, and has excellent links to the pharmaceutical industry. He also acted as the Society�s scientific spokesperson for the media. He has over 300 publications as well as the co-authorship of 7 books (including Clarke�s Analysis of Drugs and Poisons). His awards include the British Pharmaceutical Conference Science Award, Society of Analytical Chemistry Silver Medal, Philip Allen Award of the Forensic Science Society, joint award of the BUCHI 2002 Award, the Academy of Pharmaceutical Sciences Medal and the Royal Pharmaceutical Society�s Charter Gold Medal. Tony is currently a member of a number of Committees including the British Pharmacopoeia Commission.

Mr Robert Seager
Robert was Company Secretary from 2001 to 2012

Prof Martin Snowden
Professor Martin Snowden is the Head of the School of Science at the University of Greenwich. Professor Snowden is internationally acknowledged in the field of physical chemistry, pharmaceutics and formulation science with over 100 refereed publications and more than 1600 citations. Professor Snowden is a member of the Court of Governors of the University and contributes to a number of University wide initiatives and developments. Professor Snowden is a Fellow of the Royal Society of Chemistry, a Chartered Chemist and a Chartered Scientist. Professor Snowden is the current Chairman of the Academy of Pharmaceutical Science (2010-2012). Professor Snowden is a fluent Welsh speaker and in his spare time Professor Snowden enjoys fly fishing.

Prof Howard Stevens
Howard Stevens graduated with a BPharm degree from London University in 1967 followed by a PhD from Heriot-Watt University in 1970. In 1970 he entered the pharmaceutical industry and worked initially at The Boots Company (1970-74), then at ER Squibb & Sons (1974-78) before taking up the post of Head of Pharmaceutical Development with Synth�labo in Paris in 1978. Ten years later he returned to the UK to take up a board position with PolySystems Ltd (the company was later acquired and transformed into Scherer DDS Ltd). In 1995 he was appointed professor of Drug Delivery at Strathclyde University and was awarded a Pfizer Personal Chair in 1998. He is a Member of RPSGB (1971) and was made a Fellow in 1998. He is also a Fellow of the Royal Society of Chemistry. He served as Chairman of APSGB from 2001-2002. At Strathclyde, Professor Stevens leads a drug delivery research group of post-graduate and post-doctoral scientists, undertaking research in nasal delivery using bioadhesive lyophilised systems and in oral controlled release formulations. He is particularly interested in the in-vivo performance of formulations in both man and animal models and is founder and Chairman of Bio-Images Research Ltd, a spin-out company devoted to investigational research on the fate of pharmaceutical preparations in-vivo.

Prof Ijeoma Uchegbu
Ijeoma Uchegbu holds a Chair in Pharmaceutical Nanoscience at the School of Pharmacy, University of London and is Director of Postgraduate Research Studies at the School. Ijeoma obtained her PhD from the School of Pharmacy, University of London in 1994, was appointed to a lectureship within the Department of Pharmaceutical Sciences, Strathclyde University in 1997 and a Chair in Drug Delivery at Strathclyde University in 2002. In 2006 Ijeoma was appointed to the Chair in Pharmaceutical Nanoscience at the School of Pharmacy, University of London. Ijeoma�s research in pharmaceutical nanoscience has provided insights into nanoparticle design for drug delivery, producing nanosystems (nanomedicines) that promote oral drug absorption and drug transport to the brain for example. Ijeoma and Andreas Sch�tzlein have also designed an anti-cancer gene medicine that is currently in pre-clinical development. Ijeoma is the Science Secretary of the CRS, a US based learned society with over 2,000 members and with interests in the delivery of pharmaceuticals, former Chair of the Academy of Pharmaceutical Sciences of Great Britain and is the Academia Expert on the Department for Innovation University and Skills� Science Engineering and Technology Strategy for Women Expert Group. Ijeoma has been awarded various prizes for her work, the latest of which is the Department for Innovation University and Skills� Women of Outstanding Achievement in Science Engineering and Technology award. Ijeoma along with five other awardees took part in a national photographic exhibition in 2007 at various venues including the Science Museum and the British Museum. Ijeoma is the editor of two books and over 70 patents, patent applications, peer reviewed journal articles and book chapters.

Dr David Wyatt